ArticleOPEN ACCESS

Hot therapy for cold agglutinin disease

Blood
DOI: 10.1182/blood-2017-06-788463
7Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Berentsen et al report remarkably high response rates, long-term efficacy, and acceptable toxicity of rituximab with bendamustine in patients with primary cold agglutinin disease (CAD) evaluated in a prospective trial of the Nordic Group.1

Cite

CITATION STYLE

APA

Jaeger, U. (2017, July 27). Hot therapy for cold agglutinin disease. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-06-788463

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free